Posts

Nura Bio Raises $73.8M Series B to Advance SARM1 Inhibitors for Neurodegeneration

Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective small‑molecule therapies, has completed a $73.8 million Series B financing round to advance its SARM1 inhibitor pipeline for neurodegenerative diseases. Proceeds will fund clinical proof‑of‑biology studies for the two lead candidates, NB‑4746 and NB‑9402, including the Phase Ib/IIa study of NB‑4746 in amyotrophic lateral sclerosis (ALS) and the first‑in‑human Phase Ia trial of NB‑9402 in healthy volunteers. SARM1 is a neuronally enriched NAD hydrolase that acts as a central driver of axon degeneration; inhibiting it is intended to block the axon‑intrinsic metabolic cascade that leads to nerve‑fiber loss, with potential across ALS, peripheral neuropathy, and ocular neurological diseases. Sources: Nura Bio Raises $73.8M Series B for ALS SARM1 - AllSci Nura Bio raises $140 million in series A extension Nura Bio discovers new SARM1 inhibitors for neurodegeneration News & Literature | Nura Bio™...

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

AbbVie's $10.9B Move for Apogee's Long-Acting I&I Drug Candidates

Villya Announces Breakthrough Data Demonstrating Enhanced Stability and Solubility for Insulin, GLP-1s

Trace Neuroscience launches first global clinical program for TRCN‑1023 ASO in ALS

Definium's LSD Formula Produces Best Data Ever Seen in Pivotal Depression Trial, CEO Says

In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy

Sanofi's R&D chief Ashrafian exits as new CEO Garijo seeks to fix pipeline with former Roche executive Fontoura

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

Lilly allies with BioArctic

BIO 2026: Cell and gene therapy sector must break the mold to thrive

Digital tool to help identify cancer patients at risk of serious immunotherapy side effect